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1. Study Background 
 
1.1 Overview of Stereotactic Ablative Radiotherapy 
 
Stereotactic Ablative Radiotherapy (SABR), is an emerging novel radiation therapy technology. 
SABR is a specialised radiotherapy treatment planning technique that delivers a high dose of 
radiation to the target with steep dose gradients resulting in rapid dose fall off outside the target 
area. This results in a high biologically effective dose (BED) to the tumour while minimising the 
dose received by normal tissues, and could potentially minimise radiotherapy treatment toxicity 
and side effects. 
The technique requires specialist positioning equipment and/or imaging (stereotaxis, a technique 
that uses medical imaging to precisely locate in three dimensions an anatomical site to which a 
beam of radiation is directed) to confirm correct targeting (accuracy) and it can be delivered 
using either standard linear accelerators or specially designed devices which are dedicated to 
delivering stereotactic treatments. Using a small number of fractions provides the opportunity 
for cost savings compared with conventional fractionation or surgical alternatives, and may free 
up capacity within NHS radiotherapy departments.  
There is now evidence from multiple non-randomised retrospective studies demonstrating that 
SABR is associated with high local control (LC, control of the primary tumour site) rates and can 
be delivered with minimal toxicity.  For example, studies in patients with oligometastases 
(Milano et al. 2012, Salama et al. 2012, Sole et al. 2013, Navarria et al. 2014, Owen et al. 2014, 
Nuyttens et al. 2015) reported LC rates of approximately >90% at 1-year and >80% at 2-year 
follow-up. Some early findings suggest it may be possible to delay the need for systemic therapy 
and improve progression-free survival (PFS) using SABR.  Further data are required to determine 
whether these benefits translate into an overall survival (OS) benefit.  
The current SABR indications for which evidence is rapidly accumulating are:  
• oligometastatic cancer (3 or fewer sites of metastatic disease) 
• cancer that has recurred in a site treated previously treated with radiotherapy (re-
irradiation) 
• patients with hepatocellular carcinoma (HCC). 
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1.2 Commissioning through Evaluation (CtE) questions 
 
This current project has been commissioned by the National Institute for Health and Care 
Excellence (NICE) to support NHS England (NHSE) in its Commissioning through Evaluation (CtE) 
programme. CtE was launched in September 2013 and provides funding for a limited number of 
patients to access medical treatments and technologies not routinely commissioned within the 
NHS (National Health Service England 2014). SABR is one such procedure which was selected for 
CtE. The key objective of the King’s Technology Evaluation Centre (KiTEC), a NICE external 
assessment centre (EAC) based at King’s College London, is to analyse SABR related data. This 
analysis will provide information regarding the clinical effectiveness of SABR (and other 
outcomes of interest), which will assist NHS England in making its commissioning decisions. 
Specifically, the following research questions will be addressed: 
1. What is the 1-year and 2-year survival following treatment with SABR for the indications 
covered by the CtE scheme (presented as estimates with confidence intervals)?  How do 
these survival estimates compare with the target outcomes (see section 4), in terms of 
superiority or non-inferiority? 
2. Does treatment with SABR for the clinical indications covered within the CtE scheme 
increase LC? 
3. What Adverse Events occur as a result of SABR in the CtE cohort of patients?  
4. What is the patient experience of treatment with SABR for the clinical indications covered 
within the CtE programme? 
5. What is the cost-effectiveness of providing SABR in three subgroups of patients covered 
within the CtE scheme (oligometastases (liver), HCC, and pelvis re-irradiation)? 
6. What are the outcomes by indication in the CtE cohort of patients?  
7. Are there any factors from the experience of centres participating in the scheme that should 
be taken into account in terms of future service provision? 
8. Are there any research findings that have become available during the course of the CtE 
scheme that should be considered alongside the evaluative findings of the CtE scheme? 
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2. Study Purpose 
 
The purpose of this study is to provide information that will help answer the NHSE evaluation 
questions outlined in section 1.2 for the patient population receiving SABR treatment under the 
CtE project.  
 
3. Study Design 
 
This is a prospective multi-centre national database (register) project to obtain the evidence 
related to SABR that will address the research question detailed in section 1.2. The CtE 
programme is forecast to enable 750 patients a year to access SABR treatment as part of a 
formal evaluation (non-routine commissioning) programme. The Steering Group for the 
programme agreed that prospective comparative data gathering is not feasible and matching 
with published data would be subject to bias. Therefore, in the absence of comparative data, it 
was decided that the study outcomes would be assessed against target outcomes derived from 
the literature and expert advice. These are outlined below along with sources on which they are 
based (see also Table 1, Table 2 and Table 3): 
 
4. Target Outcomes 
 
1. For overall survival:  
a) For oligometastases: OS rate of approximately 70% at 1-year and 50% at 2-years with 
SABR. These estimates take into account both findings reported in the literature 
(average OS of 80% at 1-year and 60% at 2-years (Milano et al. 2012, Salama et al. 2012, 
Sole et al. 2013, Navarria et al. 2014, Owen et al. 2014, Bhattacharya et al. 2015, 
Nuyttens et al. 2015)), and the imminent exclusion of breast and prostate patients from 
CtE (who have the best reported OS) as a result of the opening of the CORE trial1.  
b) For HCC: the literature reports a 2-year OS rate of approximately 50% (Andolino et al. 
2011, Scorsetti et al. 2015). This is the best defined of the 3 SABR cohorts. In addition, 
there are numerous SRs and meta-analyses investigating the management  of HCC 
 
1 The CORE trial (Aitken, K., M. Ahmed, M. Hawkins, et al. (2014). "A trial in design: CORE 
Conventional Care or Radioablation in the treatment of Extracranial metastases." Lung Cancer 83: 
S79.) 
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patients with other treatments, such as radiofrequency ablation (RFA) (Fan et al. 2010, 
Ni et al. 2014, Qi et al. 2014, Wang et al. 2014, Zhou et al. 2014, Chen et al. 2015, Feng 
et al. 2015).  
c) For re-irradiation: this will be divided in 2 cohorts, pelvis and spine, and different targets 
will be set: 
o For pelvis: OS rate of 60% at 1-year for SABR (figure derived from the findings of 
an SR (Defoe et al. 2011) including different radiotherapy techniques which 
reported a 2-year OS rate ranging from 56 to 78.8% and clinical expertise).  
o For spine: OS rates of 60% at 1-year for SABR (figure derived from findings 
reported in literature (Choi et al. 2010, Sterzing et al. 2010, Garg et al. 2011) of 
between 60% and 70% at 1 year and clinical expertise).  
 
2. For LC 
a) For oligometastases: 1-year 90%; 2-year 70% (Milano et al. 2012, Salama et al. 2012, 
Sole et al. 2013, Navarria et al. 2014, Owen et al. 2014, Nuyttens et al. 2015). 
b) For HCC: 1 year 80% (derived from expert opinion and the literature that reports LC 
rates close to 90% (Son et al. 2010, Andolino et al. 2011, Huang et al. 2012, Bibault et al. 
2013, Eriguchi et al. 2013, Yoon et al. 2013, Sanuki et al. 2014, Takeda et al. 2014, 
Huertas et al. 2015, Kimura et al. 2015, Scorsetti et al. 2015). 
c) For re-irradiation: 50% (for both spine and pelvis, derived from expert opinion). 
 
3. For Adverse Events  
a) For oligometastases: based on the published evidence (Tree et al. 2013, Gunjur et al. 
2014) and the requirement that all CtE treatment sites receive radiotherapy planning 
accreditation, a target outcome rate for grade 3 toxicity of 10% and for grade 4-5 toxicity 
of ≤5% was set. 
b) For HCC: based on the published evidence (Son et al. 2010, Andolino et al. 2011, Huang 
et al. 2012, Bibault et al. 2013, Eriguchi et al. 2013, Yoon et al. 2013, Sanuki et al. 2014, 
Takeda et al. 2014, Huertas et al. 2015, Kimura et al. 2015, Scorsetti et al. 2015) and 
clinical expertise, a target outcome rate for grade 3 toxicity of 15% and for grade 4-5 
toxicity of 10% was set.  
c) c) For re-irradiation: a target outcome of grade 3 toxicity of 20% and grade 4-5 toxicity of 
5% was set for both the spine and the pelvis cohorts.
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Table 1: Studies characteristics for oligometastatic disease   
Study 
design 
Author  Prospective/ 
retrospective 
Number Primary 
diagnosis 
Metastatic 
Site 
Chemotherapy Comparator Outcome Results  
SR (Gunjur et al. 
2014) 
NA 45 studies Various Adrenal NR adrenalectomy, 
PCA 45 papers 
(30 
adrenalectomy, 
9 SABR and 6 
PCA) 
LC, OS, T Adrenalectomy:  
2-year LC=84% 
2-year OS=46% 
SABR: 
2-year LC=63%   
2-year OS=19% 
PCA=not enough evidence, 
High heterogeneity 
SR (Tree et al. 
2013) 
NA 28 studies Various Various NR NA OS, PFS, 
T 
≥grade 3 toxicity<10% 
Cohort (Nuyttens et al. 
2015) 
P (NTR1788) 30 Various Lung None None LC, OS, T 1-year LC=79% 
2-year OS=63%  
4-year OS=38%  
≥grade 3 acute toxicity=16%  
≥grade 3 chronic toxicity=10% 
Cohort (Bhattacharya 
et al. 2015) 
R 76 Various Various None  None  PFS, OS, 
T 
1-year OS=84.4% 
2-year OS=63.2%  
1-year PFS=49.1% 
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Study 
design 
Author  Prospective/ 
retrospective 
Number Primary 
diagnosis 
Metastatic 
Site 
Chemotherapy Comparator Outcome Results  
2-year PFS=26.2% 
No grade 3-5 toxicity 
Cohort (Owen et al. 
2014) 
P 74 Various Non-spine 
bony 
metastases 
None None LC, OS, T 1-year LC=91.8% 
1-year OS=81.4% 
1-year PFS=31.5% 
No late grade 3-4 toxicities 
Cohort (Navarria et al. 
2014) 
P 
 
76 Various 
(mainly lung 
and 
colorectal) 
Lung None None LC, OS, T 1-year LC=95% 
2-year LC=89%  
1-year OS=84.1% 
2-year OS=73%  
No grade ≥3 acute or late toxicity  
Cohort (Sole et al. 
2013) 
R 42 Various Lung, liver, 
adrenal,  
Yes None LC, OS, T 1-year OS=84% 
2-year OS=63% 
1-year LC=92% 
2-year LC=86% 
≥ grade 3 toxicity=4.7% 
Cohort (Salama et al. 
2012) 
P 62 Various Various Yes (hormonal) None PFS 1-year PFS=33.3% 
2-year PFS=22% 
1-year OS=81.5% 
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Study 
design 
Author  Prospective/ 
retrospective 
Number Primary 
diagnosis 
Metastatic 
Site 
Chemotherapy Comparator Outcome Results  
2-year OS=56.7% 
Cohort (Milano et al. 
2012) 
P 121 Various Various None None LC, OS, 
FFDM 
Breast cancer: 
2-year OS=74% 
2-year FFDM=52% 
2-year LC=87% 
Non-breast cancer: 
2-year OS=39% 
2-year FFDM=28% 
2-year LC=74% 
One case of grade 3 toxicity. 
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Table 2: Studies characteristics for re-irradiation 
Study design Author  Prospective/ 
retrospective 
Primary 
diagnosis 
Number Metastatic 
Site 
Chemotherapy Comparator Outcome Results  
Cohort (Choi et al. 
2010) 
R Various 42  Spine None None LC, OS, 
Pain, T 
1-year LC=73% 
1-year OS=68% 
65% of the patients 
reported significant 
pain relief 
1 case of > grade 3 
toxicity (2%) 
Cohort  (Garg et al. 
2011) 
P Various 59 Spine Yes None LC, OS, 
Pain,  T 
1-year LC=76% 
1-year OS=76% 
All patients 
experienced 
reduced pain levels  
1 case of grade 3 
toxicity 
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Study design Author  Prospective/ 
retrospective 
Primary 
diagnosis 
Number Metastatic 
Site 
Chemotherapy Comparator Outcome Results  
Cohort {Sterzing, 
2010 #530} 
R Various 36 Spine No None LC, OS, 
Pain, T 
1-year LC=76% 
2-year LC=63% 
1-year OS=67% 
2-year OS=58% 
All patients 
experienced 
reduced pain levels  
No cases of ≥ grade 
3 toxicity 
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Table 3: Studies characteristics for HCC 
Author Year Patients (n) Study 
design 
Prospective/ 
retrospective 
Other Tx (prior 
or concurrent) 
Comparator Outcome Results 
(Andolino et 
al. 2011) 
2011 60 Cohort P TACE  None OS, PFS, LC, 
T 
2-year LC=87% 
2-year PFS=33% 
2-year OS=47%  
Median PFS=14.1 months  
Median OS=20.4 months 
(Bibault et al. 
2013) 
2013 75 Cohort R RFA, surgery 
chemo-
embolisation,  
radiotherapy, 
chemotherapy 
None LC, PFS, OS, 
T 
1-year LC=90% 
2-year LC=90% 
1-year PFS=61.7% 
2-year PFS=31.8% 
1-year OS=78.5% 
2-year OS=50%   
One patient (1%) had  ≥grade 3 toxicity  
(Eriguchi et al. 
2013) 
2013 50 Cohort R TACE 
combined with 
SABR, RFA, PEI, 
surgery, TACE  
None T One patient (2%) had  ≥grade 3 toxicity 
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Author Year Patients (n) Study 
design 
Prospective/ 
retrospective 
Other Tx (prior 
or concurrent) 
Comparator Outcome Results 
(Huang et al. 
2012) 
2012 36 Cohort R SABR, 
chemotherapy, 
TACE, liver 
transplant,  
Matched-
historical control 
group 
OS, PFS, T 2-year OS=64% 
2-year PFS=20.8%  
One patient (3%) had  ≥grade 3 toxicity 
There was statistically significant difference in OS 
between the SABR and the non-SABR matched 
historical control 
(Kimura et al. 
2015) 
2015 65 Cohort R Surgery, RFA, 
PEI, TACE, 
TACE + SABR,  
None OS, PFS, LC, 
T 
2-year LC=100%  
2-year PFS=40% 
2-year OS=76%  
≥grade 3 late toxicity=23.1% 
(Sanuki et al. 
2014) 
2014 185 Cohort R TACE  None LC, OS, T 1-year LC=99%  
2-year LC=93% 
1-year OS=95% 
2-year OS=83% 
≥grade 3 late toxicity=13% 
(Scorsetti et 
al. 2015) 
2015 43 Cohort P None None LC, OS, PFS, 
T 
1-year LC=94.2% 
2-year LC=85.8% 
1-year OS=91.1% 
2-year OS=77.9% 
1-year PFS=41 % 
The Rayne Institute, 4th Floor, Lambeth Wing
King’s College London
St. Thomas’ Hospital, Westminster Bridge Road-
London, SE1 7EH, UK .
  v2.2  IRAS Project ID: 207942 
 
 
 
15 
Author Year Patients (n) Study 
design 
Prospective/ 
retrospective 
Other Tx (prior 
or concurrent) 
Comparator Outcome Results 
≥grade 3 late toxicity=16% 
(Son et al. 
2010) 
2010 36 Cohort NR TACE, RFA,  
PEI, surgery, 
chemotherapy 
None Toxicity  ≥grade 3 toxicity=6% 
(Takeda et al. 
2014) 
2014 63 Cohort R TACE  None OS, PFS, LC, 
T 
1-year LC=100% 
2-year LC=95% 
1-year OS=100% 
2-year OS=87%  
≥grade 3 toxicity=21% 
(Yoon et al. 
2013) 
2013 93 Cohort R TACE, TACE 
and RFA, TACE 
and PEI, TACE 
+ RFA, and PEI, 
surgery 
None OS, LC, T 1-year LC=94.8% 
3-year LC=92.1% 
1-year OS=86% 
3-year OS=53.8% 
≥grade 3 toxicity=6.5% 
(Huertas et al. 
2015) 
2015 77 Cohort  R TACE 
RFA 
Surgery 
None OS, PFS, T 1-year LC=99% 
2-year LC=99% 
1-year PFS=69.3% 
2-year PFS= 44.4% 
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Author Year Patients (n) Study 
design 
Prospective/ 
retrospective 
Other Tx (prior 
or concurrent) 
Comparator Outcome Results 
1-year OS=81.8% 
2-year OS=56.6%  
≥3 grade toxicity:  
Acute=6.4% 
Late=6% 
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5. Patient Population 
 
5.1 Eligibility criteria for the registry 
 
The inclusion criteria for the proposed registry analysis are all patients who are eligible for SABR. 
There are no ineligible patients among those receiving the procedure. The eligibility criteria for 
the SABR procedure, a separate issue, are set out below. 
 
5.2 Eligibility criteria for SABR 
 
The patient population comprises a heterogeneous cohort that includes patients eligible to 
receive SABR for oligometastases, HCC and re-irradiation of the spine and pelvic area. For each of 
these indications separate eligibility criteria are outlined below. 
 
5.2.1 Eligibility criteria for oligometastatic disease 
 
• Metastatic carcinoma with either a histologically or cytologically proven primary site or 
a male patient with a prostate-specific antigen (PSA)>50 and clinical evidence of 
prostate cancer. 
• 1-3 sites of metastatic disease (defined after appropriate imaging) which can be treated 
with stereotactic radiotherapy using a radical radiation dose.  
• A maximum of two sites of spinal metastatic disease. 
• Maximum size of 6 cm for any single metastasis (5 cm for lung or liver metastases).  
• Disease free interval > 6 months; unless synchronous liver metastases from colorectal 
primary (see liver metastases section). 
• No more than three oligometastatic sites treated in total per patient. 
• Expected life expectancy > 6 months. 
• WHO performance status ≤ 2. 
• All patients to be discussed by stereotactic multi-disciplinary team (MDT) with presence 
of, or prior discussion with a disease site specific oncologist. 
• All patients willing to attend follow up and have details collected on prospective 
database for a minimum of two years. 
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5.2.2 Eligibility criteria for HCC 
 
Inclusion Criteria 
• Patients who have been discussed by the Hepato-Pancreato-Biliary (HPB) MDT.  
• Patients with an HCC diagnosis (initial, recurrent, progressive and/or refractory to other 
therapies). 
• Unsuitable for resection, transplant or RFA. 
• Unsuitable for or refractory to transarterial hepatic chemo-embolisation (TACE) or drug 
eluting beads (DEB); no response to TACE or DEB. 
• History/physical examination including examination for encephalopathy, ascites, and 
Eastern Cooperative Oncology Group (ECOG) Scale of Performance Status 0-1. 
• Adequate haematological and organ function. 
• Barcelona clinic liver cancer (BCLC) stage: Intermediate (B) or advanced (C). 
• Liver volume minus intrahepatic gross tumour volume (GTV) > 700 cm3 and intrahepatic 
tumour GTV/liver volume ratio <80%. 
• Maximum tumour dimension 5 cm. 
• Childs-Pugh Class A only (Childs Pugh scoring system classification). 
• Life expectancy > 6 months.  
• Patients must have recovered from the effects of previous surgery, radiotherapy or 
chemotherapy with a minimum of 4 weeks break prior to SABR. 
• Suitability for treatment established in Hepatobiliary MDT and Stereotactic MDT. 
• All patients willing to attend follow up and have details collected on prospective 
database for a minimum of two years. 
 
Exclusion criteria 
• Active hepatitis or clinically significant liver failure (encephalopathy, oesophageal 
varices, portal hypertension). 
• Prior abdominal radiotherapy precluding SABR, defined as any previous radiation 
therapy in which a mean dose to the liver of 15 Gy in conventional fractionation was 
delivered or previous doses to critical normal structures that would make re-irradiation 
unsafe. Prior pelvic radiation is permitted, as long as there is no overlap between pelvic 
and liver radiation fields. 
• Clinically apparent ascites. 
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• Any one hepatocellular carcinoma tumour > 6 cm. 
• More than 5 discrete intrahepatic parenchymal foci of HCC. 
• Direct tumour extension into the stomach, duodenum, small bowel or large bowel. 
• Extrahepatic metastases or malignant nodes (that enhance with typical features of HCC) 
> 3.0 cm in sum of maximal diameters (e.g. 2 lung lesions > 2 cm). 
• Active hepatitis, prior liver transplant. 
 
5.2.3 Eligibility for re-irradiation of the spine 
 
• Metastatic carcinoma with either a histologically or cytologically proven primary site, 
carcinoma of unknown primary (CUP) with histology or cytology proven metastasis or a 
male patient with a PSA>50 and clinical evidence of prostate cancer.   
• WHO performance status ≤2. 
• Ambulatory without severe comorbidity. 
• Life expectancy of more than 6 months.   
• A maximum of two sites of spinal metastatic disease requiring treatment for pain relief 
or tumour control. 
• Assessment by spinal SABR MDT that SABR is the most appropriate modality of 
treatment. 
• No current spinal instability. 
• No cord compression. 
• No chemotherapy within 28 days. Targeted therapies should be stopped a minimum of 
14 days prior to SABR.  
• At least 6 months from initial radiotherapy course. 
• All patients willing to attend follow up and have details collected on prospective 
database. 
 
5.2.4 Eligibility for re-irradiation of the pelvis/para-aortic region 
 
• Patients with pelvic or para-aortic nodal, bony, soft tissue recurrence or positive margin 
after maximal surgery in the pelvis. 
• Life expectancy >6 months. 
• No significant toxicity from previous radiation. 
• >6 months since initial radiation treatment. 
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• Histologically confirmed malignancy. 
• WHO performance status ≤2. 
• Ambulatory without severe comorbidity, particularly no significant bowel disease.   
• No chemotherapy within 28 days. Targeted therapies should be stopped a minimum of 
14 days prior to SABR (concurrent hormone therapy is permitted).  
• Patient availability for follow up to assess radiotherapy related morbidity, pain and 
functional ability for two years. 
• Assessment in specialist SABR and site-specific MDTs. 
 
6. Sample Size 
 
As this is a CtE project and not a clinical trial a sample size calculation has not been performed. 
The analysis performed by KiTEC will be descriptive and there will be no formal, statistical 
comparisons between the CtE outcomes and the target outcomes, hence a formal sample size 
(power) calculation is not relevant here.  The number of patients receiving SABR in England as 
part of the CtE programme is fixed and dependent on the funding available from NHSE. This is 
estimated to be approximately 750 patients per year. For the total duration of the programme, 
2250 people will undergo SABR treatment for the 3 indications. Of this number, approximately 
500 patients per year (total 1500) are estimated to receive treatment for oligometastatic 
disease. For re-irradiation it is estimated that the project will recruit 150 eligible patients per 
year (total 450), and for HCC 100 eligible patients per year (total 300). 
 
7. Recruiting Centres 
 
A total of 17 sites have been selected by NHSE to provide SABR treatments for patients with 
oligometastatic disease. Of these 17 centres, 8 centres have also been selected to provide SABR 
treatments for patients eligible for re-irradiation (pelvis and spine) and 7 have been selected to 
also provide treatments for patients with primary HCC. The participating centres are listed 
below. Patient recruitment to the CtE programme will be kept under regular review by NHSE 
and, if necessary, a second round of provider selection may be undertaken. 
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7.1 Oligometastatic Disease 
 
• North Region  
• Sheffield Teaching Hospitals NHS Trust  
• The Christie NHS Foundation Trust  
• The Clatterbridge Cancer Centre NHS Foundation Trust  
• Newcastle upon Tyne Hospitals NHS Foundation Trust  
• Leeds Teaching Hospitals NHS Trust  
• South Tees Hospitals NHS Foundation Trust  
 
• Midlands and East Region  
• Nottingham University Hospitals NHS Trust  
• University Hospitals Birmingham NHS Foundation Trust  
• Mount Vernon Cancer Centre (North and East Hertfordshire NHS Foundation Trust)  
• University Hospitals of Leicester NHS Trust  
 
• London Region  
• The Royal Marsden NHS Foundation Trust  
• University College Hospitals London NHS Foundation Trust  
• Barts Health NHS Trust  
• Guys and St Thomas' NHS Foundation Trust  
 
• South Region  
• University Hospitals Bristol NHS Foundation Trust  
• Oxford University Hospital NHS Trust  
• Royal Surrey County Hospital NHS Foundation Trust 
 
7.2 Re-irradiation Pelvis and Spine 
 
• 8 of the 17 sites have been selected. 
• The Royal Marsden NHS Foundation Trust  
• Guys and St Thomas’ NHS Foundation Trust  
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• Mount Vernon Cancer Centre (North and East Hertfordshire NHS Foundation Trust)  
• Oxford University Hospital NHS Trust  
• Leeds Teaching Hospitals NHS Trust  
• Nottingham University Hospitals NHS Trust  
• University Hospitals Birmingham NHS Foundation Trust  
• Barts Health NHS Trust  
 
7.3 Hepatocellular Carcinoma 
 
• 7 of the 16 sites have been selected 
• University Hospitals Birmingham NHS Foundation Trust  
• Oxford University Hospital NHS Trust  
• Barts Health NHS Trust  
• Guys and St Thomas' NHS Foundation Trust  
• Mount Vernon Cancer Centre (North and East Hertfordshire NHS Foundation Trust)  
• Leeds Teaching Hospitals NHS Trust  
• The Royal Marsden NHS Foundation Trust  
 
8. Information Governance 
 
This project has 2 phases. Phase 1 (currently ongoing) began in mid-June 2015, when CtE for 
SABR was launched and centres started treating patients. This phase involves centres collecting 
routine clinical data and data on quality of life, pain symptoms and patient experience using 
questionnaires (see Appendix 1 for the mandatory dataset). This information is stored locally, 
with standard NHS patient consent. Phase 1 of the project is classified as an audit and all patient 
data are stored and viewed only by the patients’ clinical team. Central submission and analysis 
will only occur once information governance requirements for a national SABR database have 
been fully met (phase 2). 
 
Phase 2 will involve the transfer of patient identifiable data to the national SABR database. The 
database will be established by a database provider in another academic or NHS centre. Phase 2 
will only start after KiTEC and/or the database provider gain full ethical approval for the research 
database and R&D approval from each site (a process expected to take several months). This 
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phase will require all patients to have consented for their identifiable data to be uploaded to the 
database and subsequently analysed.  
 
9. Patient consent  
A member of the clinical team directly involved with the patient's care will explain the rationale 
of the study to the participants. This could be a clinician, a nurse or a radiographer. Trial specific 
Patient information Sheets will be given to all potential recruits to the study. These will be 
backed up by a discussion with the clinician and other members involved with the patient's 
clinical care. All patients will be seen again at least 24 hours after their initial discussion before 
written consent is taken. Patients who agree for their identifiable data to be analysed by KiTEC 
will have written consent taken at a subsequent visit. 
10. End of study definition  
The end of study will be marked by the final report submission of the complete analysis to NICE 
and NHSE.  
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11. Data collection, Management and 
Analysis 
 
11.1 Data collection 
 
Centres delivering SABR for the CtE project are obliged to record the following data for analysis 
at the end of the evaluation period: 
• Baseline clinical assessment and demographics, including treatment history.  
• LC, PFS and OS. 
• Acute toxicity and late toxicity both using the Common Terminology Criteria for Adverse 
Events (CTCAE) v 4.0. 
• Quality of life, using the EuroQol  EQ-5D questionnaire. 
• Patient experience using the ‘friends and family test’ 
(https://www.england.nhs.uk/ourwork/pe/fft/), a short generic instrument widely used 
in the NHS. 
• Pain score (if relevant; particularly for spinal or bony treatments). 
 
KiTEC has developed a data dictionary outlining in detail the data collected as part of the CtE 
project (Appendix 2). This data will be collected at baseline and at predefined follow up time 
points as outlined in  
Table 4 below. Follow up beyond 2 years should be as per routine practice. This data will add to 
the current evidence base for the SABR indications to be included in this evaluation, and help 
refine patient selection criteria if SABR was commissioned in the future. 
Table 4: Outline follow up protocol for all sites 
Clinical Form Baseline 4-6 weeks 6 months 
 
12 months 
 
18 months 
 
24 months 
 
Demographics       
Clinical Assessment – 
Baseline 
      
Clinical Assessment -       
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11.2 Data quality and completeness 
 
Data quality and completeness will be ensured through the active surveillance plan. Active 
surveillance tasks fall into 4 main categories: 
1. Agreeing a mandatory data subset 
2. Preventing and monitoring inconsistent entries 
3. Triangulation and data linkage 
4. Motivating those submitting data. 
 
11.2.1 Agreeing a mandatory data subset 
 
KiTEC acknowledges that the SABR CtE data set is extensive and this may have an impact upon 
data completeness. For this reason, KiTEC and the Data Working Group will agree a mandatory 
data subset (Appendix 1) which includes a draft list of mandatory data fields. All fields will need 
to be monitored for completeness by the database provider on a quarterly basis; however, the 
focus of the active surveillance actions will be on ensuring the mandatory data fields are 90% 
complete.  Slightly less emphasis will be placed on chasing missing data from optional data fields, 
where KiTEC aims to achieve 75% completeness.  
Table 4 outlines the clinical domains KiTEC intends to capture in the SABR CtE database and the 
time points at which data will be collected. 
In order to correctly ascertain percentage completeness for both mandatory and optional data 
fields, an algorithm will be developed that either KiTEC or the database provider will apply to 
determine the percentage of completed variables at the 6 time points. An example of the 
algorithm, which has not yet been finalised due to the mandatory fields not having been agreed 
with the Data Working Group, is included in Table 5, below.  
Follow up 
EQ-5D       
CTCAE       
Pain Score       
Patient Experience       
Radiotherapy Parameters       
Death       
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Table 5: Number of mandatory variables at each time point and calculation of percentage of missing data 
based on interim tool v0.2 
*TBC – to be computed 
To determine the number of patients for whom follow-up data is missing, KiTEC expects the 
database provider to use the system below ( 
Table 6), which is based on the date of the clinical assessment at baseline. 
Table 6: Identifying patients for whom follow-up data is missing 
Clinical Form Baseline 4-6 weeks 6 months 12 months 18 months 24 months 
Demographics 8      
Clinical Assessment – 
Baseline 
15      
Clinical Assessment - 
Follow up 
5 5 5 5 5 5 
EQ-5D 6 6 6 6 6 6 
CTCAE 1 1 1 1 1 1 
Pain Score 7 7 7 7 7 7 
Patient Experience  1     
Radiotherapy Parameters 1      
Death 1 1 1 1 1 1 
 
Required Variables (A) 44 21 20 20 20 20 
Completed Variables (B) TBC TBC TBC TBC TBC TBC 
Missing Variables (C=A-B) TBC TBC TBC TBC TBC TBC 
Percentage Missing 
(C*100/A) 
TBC TBC TBC TBC TBC TBC 
Time Point How missing patients are determined 
Baseline Patients on the SABR proforma (discussed in more detail in section 11.2.5.1 that have been 
consented for the procedure, but not yet been uploaded onto the database 
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KiTEC expects that after the quarterly data completeness checks, each centre will be provided 
with a breakdown of the following information: 
• Patients missing from the database (determined using the proforma referred to in 
section 11.2.5.1). 
• Patients for whom follow-up data is missing (ascertained using table 4, above). 
• The percentage of mandatory fields completed.  
o If this is ˂90%, KiTEC or the database provider will need to provide a breakdown 
of which patients have missing data and what clinical forms the items are 
missing from.  
• The percentage of optional fields completed.  
o If this is ˂75%, KiTEC or the database provider will need to provide a breakdown 
of which patients have missing data and what clinical forms the items are 
missing from. 
 
KiTEC or the database provider will provide a template to use for each centre. This has not been 
finalised, but a high-level example is provided in Appendix 3. In addition to sending through a 
breakdown of data completeness to each centre, the data leads and data processors at the 
centre will be contacted by telephone or email if on two consecutive quarterly data 
completeness checks for an individual centre, they note any of the following: 
 
• Mandatory fields: 
o Completion of 80% or less on both occasions. 
o A decrease of 10% or more. 
4-6 weeks Patients with baseline data obtained at least 42 days before the data completion analysis date 
that do not have data in the 4-6 week time point clinical forms 
6 months Patients with baseline data obtained at least 180 days before the data completion analysis date 
that do not have data in the 6 months’ time point clinical forms 
12 months Patients with baseline data done at least 360 days before the data completion analysis date 
that do not have data in the 12 months’ time point clinical forms 
18 months Patients with baseline data obtained at least 540 days before the data completion analysis date 
that do not have data in the 18 months’ time point clinical forms 
24 months Patients with baseline data obtained at least 720 days before the data completion analysis date 
that do not have data in the 24 months’ time point clinical forms 
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• Optional fields: 
o Completion of 55% or less on both occasions. 
o A decrease of 10% or more. 
If any of the above is noted on a third consecutive report, the Data Working Group will be 
informed and will take appropriate action.  
 
11.2.2 Interim Access Tool 
 
KiTEC has developed an interim tool for data gathering in Microsoft Access along with a user 
manual. The development of the tool was based on an iterative process that included testing and 
feedback from the SABR centres. The tool will be used only by the SABR centres to collect and 
locally store the project data until the national database developed by the UK SABR consortium is 
operational. An option (option 4 – Export Patient Grid [no NHS Number]) has been built into the 
Interim data collection tool to provide an anonymised summary report of the data completion in 
an Excel spreadsheet. KiTEC will expect centres to send returns to KiTEC on a monthly basis until 
the SABR database is operational. The summarised report will include: 
• The number of patients entered; 
• Number of forms with all mandatory fields completed; and  
• Percentage of fields that have been completed per form. 
 
A copy of the dataset included in the latest version of the tool is provided in Appendix 2. 
 
11.2.3 Repository of data from SABR database 
 
Once the database is operational, most of the active surveillance tasks for this work will be 
carried on by the database provider.  However, KiTEC will request the following: 
• Monthly aggregated data reports; 
• Quarterly full, anonymised data extracts. 
KiTEC will use these reports to perform data completeness spot-checks. A data repository will be 
developed on the KiTEC server to store these extracts. The software tools to load the data into 
the repository will depend on whether the regular data extracts from the database provider are 
incremental or cumulative. For incremental data extracts there is the risk that the merge process 
could corrupt the existing data in the repository. 
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• If the data extracts are incremental then the software tool will need to be able to merge the 
new records with the existing data in the repository; 
• If the data extracts are cumulative then the whole extract will be the repository as there will 
be no need for merging. 
 
11.2.4 Preventing and monitoring inconsistent entries 
 
Both the Interim Access Tool and the final database will be designed to be clear and user-
friendly. Well-designed questions should help to prevent inappropriate entries, however, in 
order to further minimise these, the SABR database will include validation checks.  These will be 
discussed with the database provider in detail, but are likely to include:  
• Checks on allowable range of values (e.g. only value between 0 and 10 can be entered 
for the Pain Score); 
• Checks on extreme outliers (e.g. if an age of 302 is entered); 
• Giving warnings when errors arise (this usually takes the form of a pop up screen and a 
warning that the user cannot enter further data until the error is corrected); 
• Highlighting when data entry screens are missing required variables; 
• Highlighting whole clinical forms if they have not been used.  
 
The interim tool also includes a limited number of validation checks (limited by the capabilities of 
Microsoft Access) to prevent the entry of erroneous data, including highlighting of non-allowable 
values and extreme outliers.  
Despite the mitigating measures outlined above, KiTEC anticipates there will be errors in data 
entry. As detailed in section 11.2.3Error! Reference source not found., KiTEC will receive full 
data extracts from the database provider on a quarterly basis. At this point, in addition to spot-
checking data completeness, the KiTEC project lead (Anastasia Chalkidou) will carry out checks of 
the quality of the data to ensure that no inappropriate fields have been entered. 
 
11.2.4.1 Training 
 
Data entry errors will also be prevented by appropriate training of all centres entering data. The 
database provider will provide an initial training session with all centres once the database is 
operational. They will also be on-hand to provide ad-hoc training to centres having difficulties 
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entering data. The database provider will also provide a database help desk that users can 
contact as required.   
To prevent errors in data entry whilst the Interim Access Tool is being used, KiTEC will provide 
training on its use. A handbook will also be provided to all centres. Ad hoc requests will also be 
attended to via phone or email.  
 
11.2.4.2 Data cleaning 
 
As a final check on data quality, KiTEC will clean the data once data entry has been completed. 
This will include the following steps: 
• Compiling a list of missing data and sending it to the database provider, which will then 
be expected to contact individual centres and differentiate between variables truly 
missing and variables not reported. 
• Reviewing adherence of variables to database rules (e.g. TNM cancer classification 
staging system is only entered if the primary site is prostate cancer). 
 
11.2.5 Triangulation and data linkage of register data to external 
data sources 
 
KiTEC has a multi-pronged approach to data triangulation to ensure that we obtain data on all 
patients who have received SABR under the CtE scheme.  
 
11.2.5.1 Data Proforma 
 
KiTEC will design a proforma to capture any patients that have had the SABR procedure but not 
been included in the database. This proforma will capture basic data on all patients who have 
been consented for the procedure. This will be circulated to centres by the database provider 
and centres will be required to complete and return the proforma on a quarterly basis.  It is likely 
that the proforma will be a variation of the one used for the RX070 SDR CtE project (see 
Appendix 4) and will as a minimum include the following items:  
 
• Centre 
• Responsible consultant 
• NHS Number 
• Date of Birth 
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• Gender 
• Date consented for SABR 
• If SABR was performed 
• Date SABR was performed  
• Date proforma was completed. 
 
The database provider will be expected to cross-check the number of patients listed on the 
proformas with the numbers recorded in the database. Any discrepancies should be referred to 
centres for them to clarify. 
 
11.2.5.2 HES dataset and ONS dataset 
 
Hospital Episodes Statistics (HES) is a data warehouse containing details of all admissions, 
outpatient appointments and A&E attendances at NHS hospitals in England. Centres involved 
with SABR will be submitting returns to HES monthly. The database provider will apply to HSCIC 
for access to aggregated SABR procedure numbers by centre, which they will access on a 
quarterly basis. The database provider will then need to check this number with the number of 
procedures included in the database. Should there be a discrepancy, they will need to contact 
the data lead or data processor for that centre.   
 
In addition, the database provider will need to link patient level data captured in their database 
to relevant HES/ONS records. This will enable accurate mortality data to be captured, as well as 
data on other diagnoses or procedures patients may have had at other departments (internal or 
external to the treating hospital), thus increasing the accuracy of the recording of both adverse 
event and mortality in the database. This process will require the database provider to collect 
non-anonymised patient data (NHS number as a minimum), as well as to obtain access to 
equivalently non-anonymised HES/ONS patient records. The database provider will, therefore, 
need to make a formal application to HSCIC stipulating the legal basis for linking to non-
anonymised HES/ONS patient records. 
 
HSCIC provides various means to access both HES and ONS records as detailed here. Possible 
OPCS 4.5 and ICD 10 codes that are used for the SABR procedure are listed in Appendix 5 and 6. 
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11.2.5.3 Other linkages 
 
KiTEC may also interrogate other cancer registries (e.g. National Cancer Intelligence Network), 
however, this will be for the purpose of obtaining data on comparators, rather than for active 
surveillance purposes. Subsequently, KiTEC will be interested in aggregated data and no 
identifiable data will be required. 
 
11.2.6 Motivating those submitting data 
 
The database provider will provide regular data to centres on data coverage and completeness. 
This should motivate centres to improve the quality and completeness of their data. KiTEC will 
also consider producing quarterly newsletter updates to all centres, in which benchmarking 
against other centres may be used. An example of the format this may take, created by KiTEC for 
their work with RX060 (SeHCAT), is provided in Appendix 7. 
 
11.3 Data Analysis 
 
11.3.1 Statistical Analysis 
 
The statistical analysis will address the research questions set out in section 1.2. Descriptive 
statistics will be presented to characterise the patient populations. This will include demographic 
and clinical factors.  
 
Estimates of the rates of overall survival and progression-free survival (local control) at 1 year 
and 2 years following treatment with SABR will be calculated using the Kaplan-Meier method, for 
each of the three included indications (oligometastatic disease, re-irradiation of pelvis/spine, and 
hepatocellular carcinoma).  A measure of the precision of each estimate will be provided by 95% 
confidence intervals.  Kaplan-Meier graphs will be presented for key outcomes. 
 
Survival estimates will be compared narratively with the ‘target outcomes’ for each condition 
(i.e. not using statistical tests), since the target outcomes were informed by a mixture of relevant 
literature and expert opinion, and therefore there is no appropriate ‘sampling error’ which can 
be attributed to these outcomes (a requirement of statistical tests). 
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The number and percentage of adverse events following treatment with SABR will be presented 
with 95% confidence intervals, for each of the three indications.   
 
The number and percentage of patients with a positive patient experience of SABR will be 
presented with 95% confidence intervals, for each of the three indications.  Patient experience 
will be assessed using a single question: “How likely are you to recommend our SABR service to 
friends and family if they needed similar care or treatment?” 
 
If numbers within subgroups suffice, the results of the above analyses for oligometastases may 
be stratified by location or histology. 
 
11.3.2 Health Economics Analysis 
 
The cost-effectiveness of providing SABR in cohorts of patients included in the CtE scheme 
(oligometastases, re-irradiation and HCC) will be evaluated using a commonly applied Markov 
model of cancer (Figure 1).  The model will include three states: progression free; progression; 
and death.  Progression will be defined as the failure of local control. Patients accrue costs and 
quality adjusted life expectancy for each period or time cycle they spend in either progression 
free or progression states. Patients transit in the direction of the arrows with a given probability 
at the end of each time cycle and the model is run over a defined number of cycles (periods of 
time) allowing an estimate of total costs and quality adjusted life expectancy for the cohort over 
the specified time period. 
  
The Rayne Institute, 4th Floor, Lambeth Wing
King’s College London
St. Thomas’ Hospital, Westminster Bridge Road-
London, SE1 7EH, UK .
  v2.2  IRAS Project ID: 207942 
 
 
 
34 
 
Figure 2: Three state Markov model 
 
 
11.3.3 Comparators & Model Time Horizons 
 
To maintain tractability of the analysis the economic evaluation will compare SABR with one or 
two of the most clinically appropriate comparators as agreed by the CtE data working group. 
Estimation of the costs and outcomes for cohorts receiving comparator treatments will use the 
same model on the assumption that suitable data on transition probabilities is available in the 
literature. If suitable data is not available, the model may be modified to estimate costs and 
outcomes. The relevant comparators and time horizons for the three clinical areas are detailed 
below.  
 
11.3.3.1 Oligometasteses 
 
The data working group agreed that analysis would consider liver oligometastases and relevant 
comparators would be Radio frequency ablation and Surgery.  The time horizon will be 5 years.  
 
11.3.3.2 Re-irradiation 
 
The group agreed that pelvic re-irradiation should be modelled and the comparator for the 
cohort would be Surgery (pelvic exenteration). The time horizon for the analysis will be 3 years.  
 
Progression-
free survival Progression
Death
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11.3.3.3 Hepatocellular carcinoma 
 
The group agreed that RFA and Surgery would be the most appropriate comparator for the 
cohort. The time horizon will be 3 years.  
 
11.3.4 Transition probabilities, utilities and costs 
 
The transition probabilities for patients moving between the three health states for the SABR 
cohort will be estimated from the SABR register. As survival data is being collected only for 2 
years, appropriate parametric survival functions will be used to model survival data and allow 
extrapolation beyond 2 years. The transition probabilities of patients in the comparator arms 
would primarily come from the literature. Extensive sensitivity analysis of any structural 
assumptions will be undertaken. If evidence of a difference in survival between SABR and 
comparator treatments is weak, the base case will assume no difference with the impact of 
differences in survival explored in a sensitivity analysis. 
Utilities for the health states progression free survival and progression will be estimated using 
EQ5D data collected as a part of the register. In the absence of reliable data comparing quality of 
life (QOL) in patients treated with SABR and the comparators we will use the SABR data to 
estimate QOL tariffs for the health states in the models for comparator treatments. We will 
assume that QOL is influenced by adverse events, but not treatment modality. We will model the 
quality of life data to quantify the impact of adverse events on quality of life. We will derive the 
frequency of adverse events with comparator treatments from the literature and use the model 
of QOL to predict quality of life for comparator treatments given the frequency of adverse 
events. 
Treatment costs are likely to be taken primarily from available NHS tariffs and the available 
literature. If necessary, supplemental data on the costs of providing SABR treatment will be 
derived from a brief survey of staff treating patients at SABR centres.  
 
11.3.5 Cost-effectiveness analysis 
 
Modelling will follow NICE guidance for good practice wherever possible.  A NHS perspective will 
be adopted. Costs and outcomes will be discounted at the recommended 3.5% discount rate. An 
incremental cost per Quality Adjusted Life Years (QALYs) will be estimated for SABR against the 
comparators. The recommended NICE threshold of £20,000-30,000 per QALY will be used to 
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assess the cost-effectiveness of SABR. Uncertainty in parameters used in the model will be 
addressed using probabilistic and deterministic sensitivity (e.g. one way) analysis. The 
probabilistic sensitivity analysis involves simultaneous random sampling from the likely 
distribution of each model parameter and analysis multiple times (e.g. 1,000) which provides a 
distribution of probable cost-effectiveness estimates. The results will be presented in the form of 
cost-effectiveness acceptability curves. These plots provide an estimate of the likelihood that an 
intervention would be considered cost-effective across different values for the outcome (Quality 
Adjusted Life Year).  
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Appendix 1: Suggested Mandatory Fields 
 
Clinical Form Mandatory Fields 
Demographics Site Name 
NHS number (this will never be seen by KiTEC) 
Date of Birth 
Gender 
Consent form date 
Clinical Assessment – 
Baseline 
Date of assessment 
CtE Indication 
Primary site 
Tumour marker 
Imaging modality 
Number of lines of prior systemic review 
Current systemic therapy 
Previous radiotherapy 
WHO performance status 
Treatment platform 
IGRT technique 
Intended dose fractionation for SBRT treatment 
Biological effective dose (100Gy as cutoff) 
Prior systemic therapy 
Is therapy to continue through treatment 
Clinical Assessment – 
Follow Up 
Date of assessment 
WHO performance  status 
Is there imaging to interpret 
Details of further SABR treatment 
Has there been a change in systemic therapy 
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Clinical Form Mandatory Fields 
EQ-5D Mobility 
Self-care 
Usual activities 
Pain/discomfort 
Anxiety/depression 
Your health today 
CTCAE Any toxicities 
Visual Analogue Pain 
Score 
Numeric pain rating scale 
Question 1 
Question 2 
Question 3 
Question 4 
Question 5 
Question 6 
Resource Utilisation Staffing time: Clinician 
Staffing time: Physicist 
Staffing time: Radiographer 
Daily treatment time (minutes) 
Fiducial markers 
Radiotherapy 
Parameters 
Were all planning constraints met? 
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Appendix 2: SABR Dataset 
 
SABRDatabase1401
16.xlsx
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Appendix 3: Possible template for provision of 
feedback regarding data completeness 
 
Centre Name 
Item     Comments with patient identified 
(e.g. database number) 
 Demographics 
1 Number of patients in the database 2 
 
2 Data completeness for mandatory 
fields  
95% Mandatory fields for 1 patient 
missing: 
002 
3 Data completeness for optional fields 78% √ 
 Clinical Assessment - Baseline 
4 Number of patients in database 2 
 
5 Data completeness for mandatory 
fields 
100%  √ 
6 Data completion for optional fields 50% Optional fields for 2 patients 
missing: 
001 
002 
Continued for all clinical forms 
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Appendix 4: Data proformas used for RX070 SDR 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
UK Selective Dorsal Rhizotomy (SDR) database for Commissioning through Evaluation (CtE) for SDR
ProForma to monitor SDR patients
Contact details: KiTEC - King's Technology Evaluation Centre. Phone: +44 (0) 203 299 1626
Patient Example
SDR Centre XXXXXX Hospital
Responsible Consultant Mr Pringle
NHS Number 1234567890
DOB 01/01/2010
Gender Male
Age at entry onto waiting list 3 years 2 months
Current GMFCS level II
Confirmation of SDR eligibility criteria (see below) Yes
            If not currently eligble, please explain why not: na
SDR operation performed? Yes
            If yes, date of operation: 01/02/2015
            If no, please state reasons (eg: no community physiotherapy 
available via CCG funding, or SDR funding not available) na
Has Community Physiotherapy been received? Yes
            If yes, please give start date: 01/03/2015
            If applicable, please give end date for community physiotherapy: na
            If applicable, please list type of Community Physiotherapy payment 
(CCG, private, other [state]) CCG
Any other information? na
Date of proforma completion 01/04/2015
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Appendix 5: OPCS codes (NHS National Clinical 
Analysis and Specialised Team NATCANSAT) 
OPCS4 Code Description 
Z01 Tissue Of Brain 
Z246 Lung 
Z247 Mediastinum 
Z301 Liver 
Z313 Spleen 
Z534 Peritoneal Cavity 
Z611 Cervical Lymph Node 
Z612 Scalene Lymph Node 
Z613 Axillary Lymph Node 
Z614 Mediastinal Lymph Node 
Z615 Paraaortic Lymph Node 
Z616 Inguinal Lymph Node 
Z618 Specified Lymph Node Neck 
Z619 Lymph Node Neck 
Z63 Bone Of Cranium 
Z64 Bone Of Face 
Z65 Jaw 
Z661 Atlas 
Z662 Axis Bone 
Z663 Cervical Vertebra 
Z664 Thoracic Vertebra 
Z665 Lumbar Vertebra 
Z668 Specified Vertebra Neck 
Z669 Vertebra Neck 
Z68 Bone Of Shoulder Girdle 
Z69 Humerus 
Z74 Rib Cage 
Z75 Bone Of Pelvis 
Z76 Femur 
Z87 Other Part Of Musculoskeletal System 
 
The Rayne Institute, 4th Floor, Lambeth Wing
King’s College London
St. Thomas’ Hospital, Westminster Bridge Road-
London, SE1 7EH, UK .
  v2.2  IRAS Project ID: 207942 
 
 
 
43 
Appendix 6: ICD 10 Codes 
 
Head & Neck C00 Malignant neoplasm of lip 
Head & Neck C01 Malignant neoplasm of base of tongue 
Head & Neck C02 Malignant neoplasm of other and unspecified parts 
Head & Neck C03 Malignant neoplasm of gum 
Head & Neck C04 Malignant neoplasm of floor of mouth 
Head & Neck C05 Malignant neoplasm of palate 
Head & Neck C06 Malignant neoplasm of other and unspecified parts 
Head & Neck C07 Malignant neoplasm of parotid gland 
Head & Neck C08 Malignant neoplasm of other and unspecified major 
Head & Neck C09 Malignant neoplasm of tonsil 
Head & Neck C10 Malignant neoplasm of oropharynx 
Head & Neck C11 Malignant neoplasm of nasopharynx 
Head & Neck C12 Malignant neoplasm of piriform sinus 
Head & Neck C13 Malignant neoplasm of hypopharynx 
Head & Neck C14 Malig neo, overlapping lesion of lip, oral cavity & pharynx 
Upper GI C15 Malignant neoplasm of oesophagus 
Upper GI C16 Malignant neoplasm of stomach 
Upper GI C17 Malignant neoplasm of small intestine 
Lower GI C18 Malignant neoplasm of colon 
Lower GI C19 Malignant neoplasm of rectosigmoid junction 
Lower GI C20 Malignant neoplasm of rectum 
Lower GI C21 Malignant neoplasm of anus and anal canal 
Upper GI C22 Malignant neoplasm of liver and intrahepatic bile 
Upper GI C23 Malignant neoplasm of gallbladder 
Upper GI C24 Malignant neoplasm of other and unspecified parts 
Upper GI C25 Malignant neoplasm of pancreas 
Upper GI C26 Malignant neoplasm, digestive organs 
Head & Neck C30 Malignant neoplasm of nasal cavity and middle ear 
Head & Neck C31 Malignant neoplasm of accessory sinuses 
Head & Neck C32 Malignant neoplasm of larynx 
Lung C33 Malignant neoplasm of trachea 
Lung C34 Malignant neoplasm of bronchus and lung 
Endocrine C37 Malignant neoplasm of thymus 
Musculoskeletal C38 Malignant neoplasm of heart, mediastinum and pleura 
Lung C39 Malignant neoplasm, respiratory tract 
Musculoskeletal C40 
Malignant neoplasm of bone and articular cartilage, 
unspecified 
Musculoskeletal C41 Malignant neoplasm of bone and articular cartilage 
Skin C43 Malignant melanoma of skin 
The Rayne Institute, 4th Floor, Lambeth Wing
King’s College London
St. Thomas’ Hospital, Westminster Bridge Road-
London, SE1 7EH, UK .
  v2.2  IRAS Project ID: 207942 
 
 
 
44 
Skin C44 Other malignant neoplasms of skin 
Lung C45 Mesothelioma 
Musculoskeletal C46 Kaposi's sarcoma 
Musculoskeletal C47 Malignant neoplasm of peripheral nerves and autonomic 
Musculoskeletal C48 Malignant neoplasm of retroperitoneum and peritoneum 
Musculoskeletal C49 Malignant neoplasm of other connective and soft tissue 
Breast C50 Malignant neoplasm of breast 
Gynae C51 Malignant neoplasm of vulva 
Gynae C52 Malignant neoplasm of vagina 
Gynae C53 Malignant neoplasm of cervix uteri 
Gynae C54 Malignant neoplasm of corpus uteri 
Gynae C55 Malignant neoplasm of uterus, part unspecified 
Gynae C56 Malignant neoplasm of ovary 
Gynae C57 Malignant neoplasm of other and unspecified female 
Gynae C58 Malignant neoplasm of placenta 
Urology C60 Malignant neoplasm of penis 
Urology C61 Malignant neoplasm of prostate 
Urology C62 Malignant neoplasm of testis 
Urology C63 Malignant neoplasm of other and unspecified male g 
Urology C64 Malignant neoplasm of kidney, except renal pelvis 
Urology C65 Malignant neoplasm of renal pelvis 
Urology C66 Malignant neoplasm of ureter 
Urology C67 Malignant neoplasm of bladder 
Urology C68 
Malignant neoplasm of other and unspecified urinary 
organs 
Other C69 Malignant neoplasm of eye and adnexa 
Brain/CNS C72 Malignant neoplasm of spinal cord, cranial nerves 
Endocrine C73 Malignant neoplasm of thyroid gland 
Endocrine C74 Malignant neoplasm of adrenal gland 
Endocrine C75 
Malignant neoplasm of other endocrine glands and related 
structures 
Not defined C76 Malignant neoplasm of other and ill-defined sites 
Not defined C77 
Secondary and unspecified malignant neoplasm of lymph 
nodes 
Not defined C78 
Secondary malignant neoplasm of respiratory and 
digestive organs 
Not defined C79 Secondary malignant neoplasm of other sites 
Other C80 Malignant neoplasm without specification of site 
Haematology C96 Other and unspecified malignant neoplasms of lymph 
Other C97 Malignant neoplasms of independent (primary) multi 
Musculoskeletal D16 Benign neoplasm of bone and art cartilage, unspecified 
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Appendix 7: Example of update to centres used 
for RX060 SeHCAT 
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